IL135799A0 - Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration - Google Patents

Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Info

Publication number
IL135799A0
IL135799A0 IL13579998A IL13579998A IL135799A0 IL 135799 A0 IL135799 A0 IL 135799A0 IL 13579998 A IL13579998 A IL 13579998A IL 13579998 A IL13579998 A IL 13579998A IL 135799 A0 IL135799 A0 IL 135799A0
Authority
IL
Israel
Prior art keywords
methods
nervous system
central nervous
neuronal regeneration
mammalian central
Prior art date
Application number
IL13579998A
Other languages
English (en)
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2219683 external-priority patent/CA2219683A1/en
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of IL135799A0 publication Critical patent/IL135799A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13579998A 1997-10-28 1998-10-28 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration IL135799A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2219683 CA2219683A1 (en) 1997-10-28 1997-10-28 Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
CA2251410 1998-10-16
PCT/CA1998/000997 WO1999021581A1 (en) 1997-10-28 1998-10-28 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Publications (1)

Publication Number Publication Date
IL135799A0 true IL135799A0 (en) 2001-05-20

Family

ID=25679779

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13579998A IL135799A0 (en) 1997-10-28 1998-10-28 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
IL135799A IL135799A (en) 1997-10-28 2000-04-24 Immunological compositions to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL135799A IL135799A (en) 1997-10-28 2000-04-24 Immunological compositions to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Country Status (11)

Country Link
US (2) US6969516B1 (xx)
EP (1) EP1047449B1 (xx)
JP (1) JP2001521008A (xx)
AT (1) ATE249241T1 (xx)
AU (1) AU748143B2 (xx)
DE (1) DE69818106T2 (xx)
DK (1) DK1047449T3 (xx)
ES (1) ES2210829T3 (xx)
IL (2) IL135799A0 (xx)
PT (1) PT1047449E (xx)
WO (1) WO1999021581A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4095900A (en) * 1999-04-28 2000-11-10 University Of British Columbia, The Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
ES2557056T3 (es) 2006-10-10 2016-01-21 Regenesance B.V. Inhibición del complemento para una mejor regeneración de los nervios
LT2649086T (lt) * 2010-12-09 2017-11-10 The Trustees Of The University Of Pennsylvania Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10058471B2 (en) * 2014-02-21 2018-08-28 William M. Vaughan System and method of using hyperbaric oxygen therapy for treating concussive symptoms and musculoskeletal injuries and for pre-treatment to prevent damage from injuries
KR20240042250A (ko) 2014-04-07 2024-04-01 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
KR20170134642A (ko) 2015-04-08 2017-12-06 노파르티스 아게 Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002003A1 (en) * 1989-08-04 1991-02-21 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
US6020140A (en) * 1991-08-09 2000-02-01 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
ATE187889T1 (de) * 1992-06-12 2000-01-15 Cephalon Inc Vorbeugung und behandlung der peripheren neuropathie
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US6228598B1 (en) * 1998-10-02 2001-05-08 Washington University Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies

Also Published As

Publication number Publication date
AU748143B2 (en) 2002-05-30
US6548061B1 (en) 2003-04-15
US6969516B1 (en) 2005-11-29
JP2001521008A (ja) 2001-11-06
DK1047449T3 (da) 2004-01-26
DE69818106T2 (de) 2004-06-17
WO1999021581A1 (en) 1999-05-06
IL135799A (en) 2011-01-31
ATE249241T1 (de) 2003-09-15
PT1047449E (pt) 2004-04-30
EP1047449A1 (en) 2000-11-02
EP1047449B1 (en) 2003-09-10
DE69818106D1 (de) 2003-10-16
ES2210829T3 (es) 2004-07-01
AU9617998A (en) 1999-05-17

Similar Documents

Publication Publication Date Title
IL135799A0 (en) Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
Narayanan et al. Biosynthesis and regulation of type V collagen in diploid human fibroblasts.
DK1194167T3 (da) Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
NL300372I1 (nl) Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
DE69309472T2 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE69119278D1 (de) Monoklonaler Antikörper, der mit einer neuen HLA-Determinante auf MHC-Klasse-I-Moleküle reagiert, und Verfahren zur Aktivierung von Lymphozyten
ATE47155T1 (de) Monoklonaler antikoerper.
PT743856E (pt) Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros
ES515177A0 (es) Procedimiento para el tratamiento de inmunoglobulina de suero.
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
ES8603281A1 (es) Un procedimiento para quemar hidrocarburos viscosos
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
DK121788A (da) Il-6, fremgangsmaade til dets fremstilling samt dets anvendelse
ATE403001T1 (de) Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
DE68918867T2 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
FI891528A0 (fi) Antikroppheterokonjugat foer anvaendning vid reglering av lymfocytaktivitet.
AU4626389A (en) Use of minoxidil for wound healing
CA2253078A1 (en) Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
DE69432472D1 (de) Verfahren zur hemmung der phagozytose
NO892125L (no) Kombinasjon av angiotensin-omvandlende-enzymhemmere med kaliumkanal-modulatorer samt deres anvendelse i legemidler.
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
Stolinsky et al. ON THE UNIVALENT FRAGMENTS OF HUMAN 7 S GAMMA-GLOBULIN.
Dose et al. EFFECT OF UV‐IRRADIATION ON SEDIMENTATION BEHAVIOR OF VARIOUS PROTEINS
Ikuta et al. Purification of C-reactive protein

Legal Events

Date Code Title Description
FF Patent granted